http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-0000518-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0ae29cc5ea09584f055185f6153f6f16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56 |
| filingDate | 2000-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e313c4e6533a2cda78b89f1ca9de260 |
| publicationDate | 2001-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-0000518-A |
| titleOfInvention | Formulation of hormonal precursors including sulfobutyl-ether-beta-cyclo dextrin |
| abstract | "FORMULATION OF HORMONAL PRECURSORS INCLUDED WITHOUT SULFOBUTY ETHER-BETA-CYCLODEXTRIN". The present invention concerns hormonal precursor formulations 4-androstenedione, 4-androstenediol, 19-nor-4-androstenedione ,, 19-nor-4-androstenediol, 5-androstenediol and other possible fruitful combinations (4-androstenedione + 4-androstenediol, 4-androstenediol + 19-nor-4-androstenedione, 4-androstenedione + 19-nor-4-androstenediol, 19-nor-4-androstenedione + 19-nor-4androstenediol) included in sulfobutyl ether-beta-cyclodextrin (sulfo-butyl-ether beta-cyclodextrin), which give them better solubility properties, higher absorption speed, and greater protection against first-pass oxidation and, consequently, greater bioavailability, greater precision to extended release systems and greater safety margin than formulations of these same hormonal precursors in hydroxypropyl-beta- cyclodextrin, allowing the use of lower doses than those currently used resulting in the same effects. |
| priorityDate | 2000-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 24.